Biologics Stakeholders Seek Clearer Guidance on Post-Approval Changes

Drug GMP Report
A A
The FDA’s draft guidance on post-approval manufacturing changes for biological products needs work to clarify how it fits with previous agency documents, according to written comments on the draft.

To View This Article:

Login

Subscribe To Drug GMP Report